Cobacan

Cobacan is expected to be the first product able to deliver as much cobalamin coenzyme to the bloodstream as an average cobalamin intramuscular injection. Thus sufferers of pernicious anemia are expected to to be able to replace their regimens of monthly injections by using Cobacan cherry-flavored lozenges. Pernicious anemia is usually caused by genetics, AIDS and the use of methotrexate for the treatment of rheumatoid arhtritis or cancer.

Since cobalamin (vitamin B12) is such a large molecule, it is not digested well; therefore dietary supplements, fortified foods and other sources of vitamin B12 are not treatments for pernicious anemia. The typical treatment regimen for pernicious anemia sufferers is one cobalamin injection per month, every month, for the rest of the patient's life.

In order for any form of cobalamin to be absorbed for use in the body, it must be broken down into one of two specific coenzymes, either methylcobalamin or adenosylcobalamin. Bebaas' patent-pending technology covers any combination of cyaCbl-NO30amin, the most stable molecule, with hydroxycobalamin and adenosylcobalamin. This is why Cobacan is expected to deliver so much more cobalamin to the bloodstream.

Individuals who suffer from regular heartburn, who are pregnant, who are of northern European descent, who take methotrexate (for chemotherapy or for rheumatoid arthritis) or metformin (for diabetes) or who have a family history of pernicious anemia are groups who are particularly at risk of developing pernicious anemia.

Cobalamin injections are also currently commonly prescribed for the treatment of senior dementia, fatigue, overindulgence and heart disease. Cobalamin serum levels can be depleted by long-term use of antibiotics, anti-ulcer medications, chemotherapy drugs (particularly methotrexate, which is also commonly prescribed in the treatment of rheumatoid arthritis), metformin (for diabetes) and phenobarbital and/or phenytoin (for seizure disorders). Cobalamin is also necessary for growth, cell replication, blood formation and protein and tissue synthesis.

Bebaas expects to complete final testing and receive approval for Cobacan from FDA approval by early 2008.

CblNO-30

Cbl-NO30 is essentially a combination of Cobacan with nitric oxide. Cbl-NO30 works by stimulating apoptosis, a mechanical cell-suicide, from within cancerous cells.

A variety of cancer cells develop extra transcobalamin receptors on their cell walls. This is one of the ways that cancer cells are able to grow and spread so much more aggressively than healthy cells; they horde the available cobalamin in the bloodstream. By attaching a nitric oxide molecule to the active cobalamin, many cancer cells greedily accept the cobalamin into the cells. Once inside the cell, the nitric oxide is broken off in order for the cell to utilize the cobalamin, and once separated, the nitric oxide works to stimulate apoptosis by stimulating specific caspases.

The active ingredients in Cbl-NO30 have been shown in vitro and in xenografts to be affective on 70 different types of tumor cells while being completely non-toxic to healthy cells.

Formulation studies for a Cbl-NO30 sublingual lozenge are expected to be completed in early 2008.